Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. scores highest on Anchor (55) and lowest on Nitro (17). Its PosiPenta is 38.59 out of 100, weaker than most similar companies.
On the Penta Grid this week, Metagenomi Therapeutics, Inc. is Grid #586 of 837 in the Healthcare sector in United States, and Grid #3,014 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Metagenomi Therapeutics, Inc. | 38.59 | 49 | 34 | 17 | 39 | 55 |
| BioStem Technologies, Inc. | 51.71 | 79 | 46 | 25 | 49 | 60 |
| Aligos Therapeutics, Inc. | 34.56 | 40 | 27 | 34 | 37 | 35 |
| Filana Therapeutics, Inc. | 40.75 | 45 | 53 | 15 | 67 | 25 |
| Estrella Immunopharma, Inc. | 41.19 | 0 | 42 | 21 | 88 | 55 |
| Impact BioMedical Inc. | 61.00 | 75 | 96 | 20 | 72 | 42 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -0.31 |
| P/B ratio | 0.26 |
EEarnings
| Trailing EPS | ₹-235.84 |
| Forward EPS | ₹-173.80 |
NNitro
| Price | 74.26 |
| 52-week high | 321.56 |
| 52-week low | 72.84 |
| Fall from 52-week high | 76.9% |
TTorque
| Return on equity (ROE) | -60.61% |
| Debt-to-equity | 0.34 |
AAnchor
| Beta (price swings) | 0.70 |
| Market cap | ₹280 Cr |
| Insider holding | 19.02% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Metagenomi Therapeutics, Inc.'s PosiPenta score?
Metagenomi Therapeutics, Inc.'s PosiPenta is 38.59 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Metagenomi Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Metagenomi Therapeutics, Inc. is Grid #586 of 837 in the Healthcare sector in United States, and Grid #3,014 of 4,000 in United States.
Which PosiPenta pillar is strongest for Metagenomi Therapeutics, Inc.?
Anchor (stability and dividends), with a score of 55 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Metagenomi Therapeutics, Inc.?
Nitro (momentum), with a score of 17 out of 100: much weaker than most similar companies.
Has Metagenomi Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 4.44 points, from 34.15 to 38.59.
PositoAI is for research and education only and is not investment advice.